Insulin aspart

Insulin aspart
Clinical data
Trade namesNovoLog, NovoRapid, Fiasp, others
BiosimilarsKirsty,[1] Trurapi,[2] Truvelog[3]
AHFS/Drugs.comMonograph
MedlinePlusa605013
License data
Pregnancy
category
Routes of
administration		Subcutaneous, intravenous
ATC code
Legal status
Legal status
Pharmacokinetic data
Onset of action15 minutes
Duration of action3–5 hours
Identifiers
CAS Number
PubChem CID
DrugBank
ChemSpider
  • none
UNII
KEGG
ChEMBL
CompTox Dashboard (EPA)
Chemical and physical data
FormulaC256H381N65O79S6
Molar mass5825.60 g·mol−1
 ☒NcheckY (what is this?)  (verify)

Insulin aspart, sold under the brand name NovoLog, among others, is a modified type of medical insulin used to treat type 1 and type 2 diabetes.[17] It is generally used by injection under the skin but may also be used by injection into a vein.[17] Maximum effect occurs after about 1–3 hours and lasts for 3–5 hours.[17] Generally a longer-acting insulin like insulin NPH is also needed.[17]

Common side effects include low blood sugar, allergic reactions, itchiness, and pain at the site of injection.[17] Other serious side effects may include low blood potassium.[17] Use in pregnancy and breastfeeding is generally safe.[4] It works the same as human insulin by increasing the amount of glucose that tissues take in and decreasing the amount of glucose made by the liver.[17] It is a manufactured form of human insulin; where a single amino acid has been changed, specifically a proline with an aspartic acid at the B28 position.[18]

Insulin aspart was approved for medical use in the United States in 2000.[17] In 2022, it was the 76th most commonly prescribed medication in the United States, with more than 8 million prescriptions.[19][20] Manufacturing involves yeast, which have had the gene for insulin aspart put into their genome.[21] This yeast then makes the insulin, which is harvested from the bioreactor.[22]

  1. ^ a b Cite error: The named reference Kirsty EPAR was invoked but never defined (see the help page).
  2. ^ "Approved in 2020: Drugs for human use". Health Canada. 26 July 2021. Retrieved 27 March 2024.
  3. ^ a b c Cite error: The named reference Truvelog APMDS was invoked but never defined (see the help page).
  4. ^ a b "Insulin aspart Pregnancy and Breastfeeding Warnings". Drugs.com. Archived from the original on 6 March 2019. Retrieved 3 March 2019.
  5. ^ a b "Australian Public Assessment Report for Insulin aspart" (PDF). Therapeutic Goods Administration (TGA). March 2021. Archived from the original (PDF) on 24 June 2021.
  6. ^ "Australian Public Assessment Report for Insulin aspart (rys)" (PDF). Therapeutic Goods Administration (TGA). August 2021. Archived from the original (PDF) on 5 February 2022.
  7. ^ Cite error: The named reference Truvelog Solostar ARTG was invoked but never defined (see the help page).
  8. ^ "Regulatory Decision Summary - Fiasp". Health Canada. 23 October 2014. Archived from the original on 5 June 2022. Retrieved 4 June 2022.
  9. ^ "Regulatory Decision Summary - Trurapi". Health Canada. 23 October 2014. Archived from the original on 5 June 2022. Retrieved 4 June 2022.
  10. ^ "Diabetic health". Health Canada. 8 May 2018. Retrieved 13 April 2024.
  11. ^ Cite error: The named reference NovoRapid SmPC was invoked but never defined (see the help page).
  12. ^ "Fiasp- insulin aspart injection injection, solution". DailyMed. 19 December 2019. Archived from the original on 13 November 2020. Retrieved 12 November 2020.
  13. ^ "NovoLog- insulin aspart injection, solution Insulin Diluting Medium For NovoLog- water injection injection, solution". DailyMed. 15 November 2019. Archived from the original on 12 November 2020. Retrieved 12 November 2020.
  14. ^ "NovoLog Mix 70/30- insulin aspart injection, suspension". DailyMed. 15 November 2019. Archived from the original on 29 September 2020. Retrieved 12 November 2020.
  15. ^ Cite error: The named reference NovoMix EPAR was invoked but never defined (see the help page).
  16. ^ Cite error: The named reference Truvelog Mix 30 EPAR was invoked but never defined (see the help page).
  17. ^ a b c d e f g h "Insulin Aspart Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. Archived from the original on 6 March 2019. Retrieved 3 March 2019.
  18. ^ Turner JR (2010). New Drug Development: An Introduction to Clinical Trials: Second Edition. Springer Science & Business Media. p. 32. ISBN 9781441964182. Archived from the original on 20 April 2021. Retrieved 11 September 2020.
  19. ^ "The Top 300 of 2022". ClinCalc. Archived from the original on 30 August 2024. Retrieved 30 August 2024.
  20. ^ "Insulin Aspart Drug Usage Statistics, United States, 2013 - 2022". ClinCalc. Retrieved 30 August 2024.
  21. ^ Banga AK (2005). Therapeutic Peptides and Proteins: Formulation, Processing, and Delivery Systems, Second Edition. CRC Press. p. 13. ISBN 9781420039832. Archived from the original on 20 April 2021. Retrieved 11 September 2020.
  22. ^ Schmid RD, Schmidt-Dannert C (2016). Biotechnology: An Illustrated Primer. John Wiley & Sons. p. 222. ISBN 9783527677566. Archived from the original on 20 April 2021. Retrieved 11 September 2020.